Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,414
archived clinical trials in
Overactive Bladder

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Wadsworth, OH
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Wadsworth, OH
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Bethany, OK
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Bethany, OK
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Edmond, OK
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
mi
from
Bala-Cynwyd, PA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
West Reading, PA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Warwick, RI
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Greer, SC
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Simpsonville, SC
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Arlington, TX
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Houston, TX
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Virginia Beach, VA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Mountlake Terrace, WA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Seattle, WA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Spokane, WA
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated:  11/9/2017
mi
from
Vancouver,
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Status: Enrolling
Updated: 11/9/2017
mi
from
Vancouver,
Click here to add this to my saved trials
InterStim Prospective Database
InterStim Prospective Database for Outcomes Research
Status: Enrolling
Updated:  12/21/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
InterStim Prospective Database
InterStim Prospective Database for Outcomes Research
Status: Enrolling
Updated: 12/21/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Status: Enrolling
Updated:  1/8/2018
Birmingham VAMC
mi
from
Birmingham, AL
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Status: Enrolling
Updated: 1/8/2018
Birmingham VAMC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Status: Enrolling
Updated:  1/8/2018
Atlanta VA Medical Center
mi
from
Decatur, GA
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Status: Enrolling
Updated: 1/8/2018
Atlanta VA Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
Urodynamic Testing: Can we Improve Patient Experience?
A Telephone Call to Decrease Patient Anxiety Before Urodynamic Testing: a Randomized Controlled Trial
Status: Enrolling
Updated:  1/17/2018
Mount Auburn Hospital
mi
from
Cambridge, MA
Urodynamic Testing: Can we Improve Patient Experience?
A Telephone Call to Decrease Patient Anxiety Before Urodynamic Testing: a Randomized Controlled Trial
Status: Enrolling
Updated: 1/17/2018
Mount Auburn Hospital
mi
from
Cambridge, MA
Click here to add this to my saved trials
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Status: Enrolling
Updated:  1/26/2018
The Christ Hospital
mi
from
Cincinnati, OH
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?
Status: Enrolling
Updated: 1/26/2018
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oxybutynin and Omega-3 for OAB (Overactive Bladder)
Randomized Controlled Trial of Oxybutynin and Omega-3 Fatty Acid Supplementation Versus Oxybutynin and Placebo for Treatment of Overactive Bladder in Women
Status: Enrolling
Updated:  1/29/2018
Good Samaritan Hospital
mi
from
Cincinnati, OH
Oxybutynin and Omega-3 for OAB (Overactive Bladder)
Randomized Controlled Trial of Oxybutynin and Omega-3 Fatty Acid Supplementation Versus Oxybutynin and Placebo for Treatment of Overactive Bladder in Women
Status: Enrolling
Updated: 1/29/2018
Good Samaritan Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bladder Environment: Microbiome Oxygen Relationship
Bladder Environment: Microbiome Oxygen Relationship
Status: Enrolling
Updated:  2/19/2018
Loyola University Health System
mi
from
Maywood, IL
Bladder Environment: Microbiome Oxygen Relationship
Bladder Environment: Microbiome Oxygen Relationship
Status: Enrolling
Updated: 2/19/2018
Loyola University Health System
mi
from
Maywood, IL
Click here to add this to my saved trials
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.
Status: Enrolling
Updated:  3/1/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.
Status: Enrolling
Updated: 3/1/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.
Status: Enrolling
Updated:  3/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.
Status: Enrolling
Updated: 3/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial
Status: Enrolling
Updated:  3/1/2018
Henry Ford Hospital
mi
from
Detroit, MI
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial
Status: Enrolling
Updated: 3/1/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial
Status: Enrolling
Updated:  3/1/2018
Henry Ford West Bloomfield Hospital
mi
from
West Bloomfield, MI
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial
Status: Enrolling
Updated: 3/1/2018
Henry Ford West Bloomfield Hospital
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Status: Enrolling
Updated:  3/7/2018
UAB Continence Clinic at The Kirklin Clinic
mi
from
Birmingham, AL
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Status: Enrolling
Updated: 3/7/2018
UAB Continence Clinic at The Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder
Status: Enrolling
Updated:  3/8/2018
Lahey Clinic
mi
from
Burlington, MA
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder
Status: Enrolling
Updated: 3/8/2018
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Uro-NIRS Clinical Study
Uro-NIRS Clinical Study
Status: Enrolling
Updated:  3/12/2018
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Uro-NIRS Clinical Study
Uro-NIRS Clinical Study
Status: Enrolling
Updated: 3/12/2018
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Reducing Postoperative Catheterization
Reducing Postoperative Catheterization After Urogynecology Surgery: A Randomized Trial
Status: Enrolling
Updated:  3/15/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Reducing Postoperative Catheterization
Reducing Postoperative Catheterization After Urogynecology Surgery: A Randomized Trial
Status: Enrolling
Updated: 3/15/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy
Clinical Assessment of Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy
Status: Enrolling
Updated:  4/9/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy
Clinical Assessment of Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy
Status: Enrolling
Updated: 4/9/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Oakwood Hospital
mi
from
Dearborn, MI
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Oakwood Hospital
mi
from
Dearborn, MI
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
University of Utah
mi
from
Salt Lake City, UT
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
USCD Medical Center
mi
from
La Jolla, CA
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
USCD Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Kaiser Permanente
mi
from
San Diego, CA
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Beaumont Hospital
mi
from
Royal Oak, MI
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Duke University
mi
from
Durham, NC
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Cleveland Clinic
mi
from
Cleveland, OH
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated:  4/30/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Anticholinergic vs. Botox Comparison Study
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence
Status: Enrolling
Updated: 4/30/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated:  4/30/2018
University of Alabama at Birmingham, Department of Obstetrics and Gynecology
mi
from
Birmingham, AL
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated: 4/30/2018
University of Alabama at Birmingham, Department of Obstetrics and Gynecology
mi
from
Birmingham, AL
Click here to add this to my saved trials
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated:  4/30/2018
University of California, San Diego, Women's Pelvic Medicine Center
mi
from
La Jolla, CA
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated: 4/30/2018
University of California, San Diego, Women's Pelvic Medicine Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated:  4/30/2018
University of New Mexico Health Sciences Center
mi
from
Albuquerque, NM
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated: 4/30/2018
University of New Mexico Health Sciences Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated:  4/30/2018
Duke Division of Urogynecology and Reconstructive Pelvic Surgery
mi
from
Durham, NC
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Status: Enrolling
Updated: 4/30/2018
Duke Division of Urogynecology and Reconstructive Pelvic Surgery
mi
from
Durham, NC
Click here to add this to my saved trials